Purpose: Hundreds of high-quality organs from HCV-positive donors are ruled out or discarded annually. Transplanting these organs into HCVnegative recipients is a feasible way to optimize organ utilization, as anti-HCV therapy is now effective in the post-transplant setting. Recent data confirm the safety of transplanting HCV-positive organs into HCV-negative recipients, who then undergo anti-HCV therapy; moreover, reported transplant outcomes are excellent. Experience has been gained in both abdominal and thoracic transplant recipients. These data will be presented in detail by Dr. David Goldberg, a national thought-leader on this topic and one of the pioneers of this strategy.
Objectives: At the end of the webinar, participants should be able to:
- Identify the number of organs discarded annually due to HCV infection in deceased donors.
- Discuss the effectiveness of anti-HCV therapy in the post-transplant setting.
- Summarize outcomes associated with transplanting HCV-positive organs into HCV-negative recipients.